KZIA - KAZIA THERAPEUTICS LTD
11.53
1.290 11.188%
Share volume: 1,079,011
Last Updated: 04-22-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.18%
PREVIOUS CLOSE
CHG
CHG%
$10.24
1.29
0.13%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
9.91%
1 Month
61.94%
3 Months
53.53%
6 Months
71.07%
1 Year
246.77%
2 Year
2,818.99%
Key data
Stock price
$11.53
DAY RANGE
$10.36 - $12.36
52 WEEK RANGE
$3.05 - $17.40
52 WEEK CHANGE
$237.39
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
Company detail
CEO: James S. Garner
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: kaziatherapeutics.com
Employees: 12
IPO year: 1999
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.
Recent news